Abstract
Like much of the clinical research and health care provider enterprise, the data capture and archiving for harm, probability of harm, and impact of intervention-related events is fragmented, inconsistent, and lacks standards to perform the types of operations that could inform researchers, practitioners, and patients in a timely way of actions and policies. The entire system of assessments, terminology, data formats and structure, analyses, and dissemination would benefit from changes based on adherence to a process framework of detect, describe, analyze, and react in the context of recognizing the multiple pathways and factors that lead to any specific outcome or series of outcomes. Existing tools, if properly applied, can form the basis for the next generation of data systems, processes, analyses, and sharing to address most of the current challenges.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zins GR. The history of the development of minoxidil. Clin Dermatol. 1988;6(4):132–147.
Goldstein I, Burnett AL, Rosen RC, Park PW, Stecher VJ. The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction. Sex Med Rev. 2019;7(1):115–128.
Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations [published ahead of print October 12, 2018]. Nat Rev Drug Discov. doi:10.1038/nrd.2018.168.
Duggirala HJ, Tonning JM, Smith E, et al. Use of data mining at the Food and Drug Administration. J Am Med Inform Assoc. 2015; 23(2):428–434.
Gini R, Schuemie M, Brown J, et al. Data extraction and management in networks of observational health care databases for scientific research: a comparison among EU-ADR, OMOP, mini-sentinel and MATRICE strategies. EGEMS (Wash DC). 2016; 4(1):1189.
Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3:160026.
Banda JM, Callahan A, Winnenburg R, et al. Feasibility of prioritizing drug–drug-event associations found in electronic health records. Drug Saf. 2015;39(1):45–57.
Li Y, et al. A method to combine signals from spontaneous reporting systems and observational healthcare data to detect adverse drug reactions. Drug Saf. 2015;38(10):895–908.
Hardin AP, Hackell JM. Age limit of pediatrics. Pediatrics. 2017; 140(3):e20172151.
FDA. CDRH pediatrics. https://www.fda.gov/medicaldevices/productsandmedicalprocedures/ucm135104.htm. Accessed October 30, 2018.
FDA. Additional protections for children. https://www.fda.gov/scienceresearch/specialtopics/runningclinicaltrials/ucm119111.htm. Accessed October 30, 2018.
Becker ML, Leeder JS. Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics. 2010;11(11):1591–1602.
Murgatroyd C, Spengler D. Epigenetics of early child development. Front Psychiatry. 2011;2;16.
Rojo D, et al. Exploring the human microbiome from multiple perspectives: factors altering its composition and function. FEMS Microbiol Rev. 2017;41(4):453–478.
Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014;77(4):704–714.
Department of Health and Human Services. Human subject protection regulations. https://www.hhs.gov/ohrp/sites/default/files/ohrp/policy/ohrpregulations.pdf. Accessed October 30, 2018.
Department of Defense. Human subject protection regulations 32CFR219. https://www.ecfr.gov/cgi-bin/text-dx?tpl=/ecfrbrowse/Title32/32cfr219_main_02.tpl. Accessed October 30, 2018.
FDA. Human protection regulations 21CFR50. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50. Accessed October 30, 2018.
NCI. Common toxicity terminology for adverse events. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed October 30, 2018.
Office of Human Research Protections, Department of Health and Human Services. Unanticipated problems reporting guidance. https://www.hhs.gov/ohrp/regulations-and-policy/guidance/reviewing-unanticipated-problems/index.html#AB. Accessed October 30, 2018.
de Bie S, Ferrajolo C, Straus SM, et al. Pediatric drug safety surveillance in FDA-AERS: a description of adverse events from GRiP project. PLoS One. 2015;10(6):e0130399.
Gipson DS, Kirkendall ES, Gumbs-Petty B, et al. Development of a pediatric adverse events terminology. Pediatrics. 2017;139(1).
Clinical Data Interchange Standards Consortium. Data standards. https://www.cdisc.org/standards. Accessed October 30, 2018.
Park YR. CDISC transformer: a metadata-based transformation tool for clinical trial and research data into CDISC standards. KSII Trans Internet Inform Syst. 2011;5(10).
Braunstein ML. SMART on FHIR, in Health Informatics on FHIR: How HL7’s New API Is Transforming Healthcare. Cham, Switzerland: Springer International Publishing; 2018:205–225.
Moran A, Jacobs DR Jr, Steinberger J, et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes. 1999;48(10):2039–2044.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hirschfeld, S., Zajicek, A. What Could the Future of Safety Monitoring Look Like?. Ther Innov Regul Sci 53, 590–600 (2019). https://doi.org/10.1177/2168479019854339
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479019854339